Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation.
OBJECTIVE
To investigate the long-term outcome of autoimmune disease following allogeneic bone marrow transplantation (BMT), and its relationship to hemopoietic chimerism.


METHODS
Three previously described patients with rheumatoid arthritis (RA) who underwent allogeneic BMT for therapy-related severe aplastic anemia and 1 new patient with psoriasis who received BMT for chronic myeloid leukemia (CML) were followed up. Molecular studies were performed to assess hemopoietic and immune reconstitution in 3 cases.


RESULTS
In 2 of the RA patients, the RA remained in remission without treatment, with nonprogressive disease, 11 and 13 years after BMT. The third patient with RA had a relapse 2 years after BMT, although the previously aggressive disease subsequently ran an attenuated course with treatment-free remission for the last 11 years. Comparison with other cases of RA suggests that graft-versus-host disease may influence the long-term outcome, perhaps through ongoing inhibition of the immune system. In the patient with psoriasis, BMT was followed by remission, but the psoriatic rash recurred and arthropathy developed 12 months later. The psoriasis and arthropathy remained active 4.5 years post-BMT, although the CML remained in remission. Molecular studies in the 2 patients whose RA remained in continued remission and in the patient with psoriasis that relapsed confirmed complete donor hemopoietic reconstitution.


CONCLUSIONS
Long-term followup of autoimmune disease after allogeneic transplantation confirmed cure of the autoimmune disease in some, but eventual relapse in others. The occurrence of relapse despite complete donor hemopoietic reconstitution is evidence for the development of de novo, as opposed to persistent, disease, and is possibly related to intrinsic susceptibility of the transplanted stem cells or to host factors. There may be a relationship between remission of autoimmune disease and graft-versus-host reaction. These findings have relevance for the evolving application of stem cell transplantation as a therapy for autoimmune diseases.
Snowden
J A
JA
St. Vincent's Hospital, Sydney, Australia.
Kearney
P
P
Kearney
A
A
Cooley
H M
HM
Grigg
A
A
Jacobs
P
P
Bergman
J
J
Brooks
P M
PM
Biggs
J C
JC
D000328:Adult; D000741:Anemia, Aplastic / Q000139:chemically induced / Q000503:physiopathology / Q000601:surgery; D018501:Antirheumatic Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000601:surgery*; D016026:Bone Marrow Transplantation; D005260:Female; D006410:Hematopoiesis / Q000502:physiology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000503:physiopathology / Q000601:surgery; D008137:Longitudinal Studies; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications; D011859:Radiography; D012008:Recurrence; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D018501:Antirheumatic Agents